MTRC released a report on HTA landscape and all published non-drug HTAs in Europe in 2018

17

May 2019

Health technology assessment plays a big role in adoption of medical technologies in Europe. However, due to large number of HTA organizations and complexity of HTA schemes, the activity and their impact on reimbursement and funding decisions is not well understood.

We developed an overview of all non-drug HTAs in 2018 to help industry to understand HTA landscape, the role of individual HTA organizations, their activity in relation to number of HTA reports and types of technologies covered.

Key features of the report:

  • 12 EU countries: HTA organizations from 12 EU countries (Austria, Belgium, Denmark, England, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, Switzerland) + EUnetHTA
  • 51 HTA organizations: All existing organizations are reviewed including EUnetHTA, national and regional HTA bodies
  • Medical devices, IVD tests and e-health solutions: Data about all non-drug assessments are included into the report
  • Overview of individual organizations: Brief overview of the role of each organization is provided
  • Summary statistics: Number of reports per country, per HTA body (program), per type of technology (e.g. neurostimulator, cardiovascular) is included
  • List of all published reports (>850): All HTA reports per country/organization are listed in the table format including organization, title, type of technology and web-link. Optionally, access the full list in MS Excel

You can learn more and download sample pages here.

The latest related news

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more

10

Mar 2022

In February 2022, the Finnish Coordinating Center for Health Technology Assessment announced the release of the seven accomplished rapid hospital assessments performed by the Helsinki, Tampere, and Oulu University Hospital. The accomplished rapid HTAs concern the diagnostic imaging, e-Health, endocrine, endoscopy, men’s health, neuromodulation technology groups.

Read more

08

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

Read more